Capricor Therapeutics, Inc. (CAPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.40+1.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Obtain FDA approval for Deramiocel: FDA approval pending vs target by end of 2027.
Capricor aims for FDA approval of Deramiocel, a key cell therapy for DMD cardiomyopathy. The company targets cash sufficiency through Q4 2027 to fund operations. Despite losses, the stock implies 31% growth over 3 years. Legal action against Nippon Shinyaku may improve pricing terms.
Capricor has missed earnings multiple times and faces ongoing litigation risks. The company remains unprofitable with negative free cash flow yield of -15%. FDA approval is uncertain, and revenue estimates for 2026 and 2027 remain low around $118M and $122M. The recent 37% share price drop reflects these risks.
The market prices in a 31% implied 3-year growth and values the stock near $9.70 fair value. Our view is cautious given ongoing losses and regulatory risks, suggesting the current price partly reflects optionality rather than confirmed growth.
Breaks if: Cash falls below levels needed to cover expenses through Q4 2027
Breaks if: FDA approval not granted by end of 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment, as CAPR is working towards FDA approval for its treatment and preparing for a commercial launch. The current thesis state reflects mixed signals from management and recent performance, indicating a cautious approach.
The market appears to be pricing in a moderate level of risk, as indicated by a low fragility tier. However, the valuation shows a premium compared to peers, suggesting that expectations may be elevated relative to its recent financial performance.
Fundamentals are likely to remain weak in the near term due to ongoing losses and a challenging operating environment. Management has stated that cash reserves are sufficient through late 2027, but the recent financial performance has been below industry standards.
The thesis hinges on several factors, including the outcome of the FDA review for Deramiocel, the ability to prepare for its commercial launch, and the overall performance of the healthcare sector. Any negative guidance or worsening economic indicators could impact sentiment significantly.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Roth Capital expects a longer FDA review. This could delay the decision on deramiocel by three months. An advisory panel voted against the drug's effectiveness for cardiomyopathy. This raises doubts about its approval. The company missed earnings expectations in its latest report.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Pursue full FDA approval for Deramiocel, an investigational cell therapy for DMD cardiomyopathy.
Breaks if: Unfavorable litigation outcome or prolonged unresolved dispute
In the next 1 to 3 years, CAPR's prospects depend on regulatory outcomes and market conditions. Not investment advice.